Prognosis
Longer Gap Between Pfizer Doses Boosts Antibodies, Study Finds
- Extended intervals between shots also boosted helper T cells
- Effect seen in variants of concern, including delta strain
This article is for subscribers only.
An interval of eight to 10 weeks between doses of the Covid-19 vaccine developed by Pfizer Inc. and BioNTech SE boosts the effectiveness of the two-shot regimen compared with a shorter interval, a U.K. study found.
“Eight weeks is probably the sweet spot,” in terms of the trade-off between getting as many people fully vaccinated as quickly as possible and allowing the population to produce higher antibody levels, professor Susanna Dunachie, the study lead from the University of Oxford, said at a briefing Thursday.